Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Epizyme, Inc. EPZM
$1.47
На 18:00, 12 мая 2023
+308.16%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
5.80
-
week52low
0.41
-
Revenue
37427000
-
P/E TTM
-2
-
Beta
-0.41805600
-
EPS
-2.08700000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 авг 2022 г. в 04:00
Описание компании
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cowen & Co. | Market Perform | Outperform | 28 июн 2022 г. |
| Wedbush | Neutral | Outperform | 27 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 03 июн 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 02 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Conroy Kevin T | D | 0 | 8994 | 12 авг 2022 г. |
| Conroy Kevin T | D | 8994 | 53324 | 12 авг 2022 г. |
| GOLDFISCHER CARL | D | 0 | 3380951 | 12 авг 2022 г. |
| GOLDFISCHER CARL | D | 8994 | 13060 | 12 авг 2022 г. |
| Giordano Michael F | D | 0 | 8994 | 12 авг 2022 г. |
| Giordano Michael F | D | 8994 | 8060 | 12 авг 2022 г. |
| Richon Victoria | D | 0 | 8994 | 12 авг 2022 г. |
| Richon Victoria | D | 8994 | 13614 | 12 авг 2022 г. |
| MOTT DAVID M | D | 0 | 106959 | 12 авг 2022 г. |
| MOTT DAVID M | D | 0 | 8994 | 12 авг 2022 г. |
Новостная лента
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Zacks Investment Research
10 авг 2022 г. в 16:33
Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
09 авг 2022 г. в 09:47
Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Epizyme Stock Is Soaring Today
The Motley Fool
27 июн 2022 г. в 12:24
A buyout ends Epizyme's 15-year tenure as an independent biopharma.
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Benzinga
27 июн 2022 г. в 07:02
Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share. The deal is expected to close by Q3.
Ipsen to acquire U.S.-based Epizyme for $247 million.
Market Watch
27 июн 2022 г. в 02:12
By Joshua Kirby